/

ENVB

Enveric Biosciences, Inc.Closed

1.40−0.07 −4.76%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.34 −4.29%

Open

1.43

Prev close

1.47

Day range

1.381.49

52-week range

1.1713.25

Volume

100.67K0.97×

Mkt cap

6.27M

P/E ttm

—

Fwd P/E

-0.99

EPS ttm

-13.01

Div yield

0.00%

Earnings

—

From 52w high

−89.43%

Price Chart

Yahoo Finance · delayed

ENVBOct 13, 2026O 1.43H 1.49L 1.38C 1.40−0.07 (−4.76%)Vol 102.10K

SMA 501.48
SMA 2002.18

1Y change −81.94% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ENVB Enveric Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.76%
1 month: −1.41%
3 months: +6.06%
6 months: −28.21%
Year to date: −61.43%
1 year: −81.94%

Valuation & ownership

Market cap: 6.27M
Enterprise value: −2.03M
P/E (ttm): —
Forward P/E: -0.99
PEG ratio: —
Price / book: 0.68
Price / sales (ttm): —
EV / EBITDA: 0.24
EPS (ttm): -13.01
EPS (forward): -1.41
Beta (5y monthly): 1.18
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 4.48M
Float: 4.34M
Short % of float: 0.35%
Short ratio (days): 0.25
Held by insiders: 8.89%
Held by institutions: 12.02%
Avg volume (3m): 104.07K
50-day average: 1.48
200-day average: 2.20
52-week change: −81.94%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 41.9
vs 50-day SMA: −5.24%
vs 200-day SMA: −35.85%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.61%
Realised vol (20d, ann.): 45.9%
From 52-week high: −89.43%
From 52-week low: +19.66%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Enveric Biosciences, Inc.

Yahoo Finance profile

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 5
Headquarters: Cambridge, MA, United States
Website: enveric.com
Officers: Dr. Joseph Edward Tucker Ph.D. CEO & Director
Mr. Kevin M. Coveney CPA Chief Financial Officer
Dr. Peter J. Facchini Ph.D. Chief Innovation Officer

SEAS

Seasonality · ENVB

2015–2026 · monthly returns

Strongest month Jun +15.20%Weakest month Oct −18.43%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-19.8	-19.2	-17.4	103.6	-41.8	-40.0	13.8	-12.7	8.4	-5.7			−61.4%
2025	-97.4	34.0	-50.4	-5.0	-10.6	2.5	0.8	-7.4	-43.5	-25.7	0.7	-36.8	−99.6%
2024	-42.9	95.4	-31.0	-6.0	-17.0	-19.7	-24.9	7.9	-6.5	5.3	-33.9	8.5	−72.5%
2023	38.0	-27.2	-20.4	10.0	128.8	-19.6	-19.0	-20.9	10.2	-26.5	-15.4	-12.2	−37.5%
2022	-31.6	-56.8	20.0	-18.2	-26.7	8.1	-40.2	-12.8	-24.4	-19.2	-15.8	-27.5	−95.5%
2021	150.0	-7.6	-10.2	-22.5	-6.3	6.7	-19.7	4.2	4.0	-15.0	-26.1	-28.5	−37.2%
2020	-42.0	-12.4	-16.3	-5.2	45.1	17.4	19.4	-31.4	8.7	-15.2	35.9	-76.7	−83.6%
2019	32.2	42.2	2.4	0.9	-8.3	12.9	-17.1	-26.2	-20.6	-23.5	-34.8	6.6	−48.0%
2018	-17.7	-14.5	-24.8	-29.9	-32.2	32.1	38.8	2.9	-11.6	-75.0	-26.2	-27.5	−94.4%
2017	0.0	0.6	-0.6	0.0	0.0	38.2	-27.7	5.2	-5.0	0.0	-57.8	12.7	−52.4%
2016	-8.8	8.0	7.7	-7.0	0.0	0.0	0.0	0.0	7.5	-7.0	0.0	0.0	−1.4%
2015						88.6	10.9	16.1	27.8	-0.9	8.9	12.6	+277.1%

INSD

Insider Activity · ENVB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
May 31, 2026	Webb Michael DDirector	Stock Award(Grant) at price 0.00 per share.	18.5K	—
May 31, 2026	Pasqualone FrankDirector	Stock Award(Grant) at price 0.00 per share.	18.5K	—
May 31, 2026	Schabacker MarcusDirector	Stock Award(Grant) at price 0.00 per share.	18.5K	—
May 31, 2026	Kegler George A. JrDirector	Stock Award(Grant) at price 0.00 per share.	18.5K	—
May 31, 2026	Tucker Joseph EdwardChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	201.1K	—
May 31, 2026	Facchini Peter JamesOfficer	Stock Award(Grant) at price 0.00 per share.	25K	—
May 31, 2026	Coveney Kevin MichaelChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	133.3K	—
May 31, 2026	Dewitt SheilaDirector	Stock Award(Grant) at price 0.00 per share.	18.5K	—
Dec 22, 2025	Webb Michael DDirector	Stock Award(Grant) at price 0.00 per share.	7.6K	—
Dec 22, 2025	Pasqualone FrankDirector	Stock Award(Grant) at price 0.00 per share.	7.6K	—
Dec 22, 2025	Schabacker MarcusDirector	Stock Award(Grant) at price 0.00 per share.	7.6K	—
Dec 22, 2025	Kegler George A. JrDirector	Stock Award(Grant) at price 0.00 per share.	7.6K	—
Dec 22, 2025	Tucker Joseph EdwardChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	60.3K	—
Dec 22, 2025	Coveney Kevin MichaelChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	40.2K	—
Dec 22, 2025	Dewitt SheilaDirector	Stock Award(Grant) at price 0.00 per share.	7.6K	—
May 7, 2025	Tucker Joseph EdwardChief Executive Officer	—	98.9K	—
May 7, 2025	Facchini Peter JamesChief Technology Officer	—	24.7K	—
May 7, 2025	Coveney Kevin MichaelChief Financial Officer	—	74.2K	—

13F

Investors Holding ENVB

latest 13F filings of 29 followed managers

Investors holding ENVB
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$44.2K	0.00%	32.06K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ENVB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ENVB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Enveric Biosciences, Inc.

Seasonality · ENVB

Insider Activity · ENVB

Congress Trades · ENVB

Investors Holding ENVB

Investors Holding ENVB

Congress Trades · ENVB

Insider Activity · ENVB

Seasonality · ENVB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Enveric Biosciences, Inc.

Earnings & Dividends

News